Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computational Biology | 5 | 2018 | 293 | 0.780 |
Why?
|
| Gene Frequency | 1 | 2017 | 195 | 0.590 |
Why?
|
| Minority Groups | 2 | 2021 | 596 | 0.560 |
Why?
|
| Drug Design | 5 | 2016 | 162 | 0.490 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 767 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2010 | 182 | 0.440 |
Why?
|
| Algorithms | 3 | 2012 | 465 | 0.430 |
Why?
|
| Software | 3 | 2010 | 217 | 0.430 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 173 | 0.390 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 182 | 0.380 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2007 | 46 | 0.350 |
Why?
|
| Obesity | 1 | 2017 | 1067 | 0.340 |
Why?
|
| Healthcare Disparities | 4 | 2019 | 494 | 0.340 |
Why?
|
| Receptors, Nicotinic | 1 | 2009 | 106 | 0.330 |
Why?
|
| Anti-HIV Agents | 2 | 2010 | 420 | 0.320 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 215 | 0.310 |
Why?
|
| Computer-Aided Design | 1 | 2007 | 11 | 0.310 |
Why?
|
| Transcription, Genetic | 3 | 2007 | 578 | 0.300 |
Why?
|
| Alcoholism | 1 | 2009 | 240 | 0.280 |
Why?
|
| Ribonucleases | 1 | 2005 | 30 | 0.270 |
Why?
|
| Models, Molecular | 5 | 2010 | 808 | 0.250 |
Why?
|
| Temperature | 1 | 2005 | 286 | 0.240 |
Why?
|
| HIV-1 | 2 | 2007 | 706 | 0.240 |
Why?
|
| Bone Marrow Diseases | 3 | 2007 | 4 | 0.220 |
Why?
|
| Gene Products, tat | 3 | 2007 | 35 | 0.210 |
Why?
|
| Amino Acid Sequence | 6 | 2016 | 1180 | 0.200 |
Why?
|
| Humans | 22 | 2021 | 37093 | 0.180 |
Why?
|
| Sequence Analysis, Protein | 2 | 2012 | 50 | 0.180 |
Why?
|
| Research | 1 | 2021 | 163 | 0.170 |
Why?
|
| Breast Neoplasms | 7 | 2007 | 1502 | 0.170 |
Why?
|
| Protein Binding | 4 | 2010 | 972 | 0.170 |
Why?
|
| Proteins | 3 | 2010 | 369 | 0.160 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 88 | 0.150 |
Why?
|
| Molecular Sequence Data | 4 | 2009 | 1568 | 0.150 |
Why?
|
| Minority Health | 1 | 2018 | 88 | 0.150 |
Why?
|
| Bone Marrow Cells | 2 | 2007 | 81 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2019 | 325 | 0.140 |
Why?
|
| Trypanocidal Agents | 1 | 2016 | 39 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 333 | 0.130 |
Why?
|
| Tubulin | 1 | 2016 | 88 | 0.130 |
Why?
|
| Chagas Disease | 1 | 2016 | 98 | 0.130 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2007 | 32 | 0.120 |
Why?
|
| Trypanosoma cruzi | 1 | 2016 | 149 | 0.120 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2016 | 269 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 628 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 807 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2008 | 400 | 0.110 |
Why?
|
| Fluorouracil | 6 | 2007 | 34 | 0.110 |
Why?
|
| Methotrexate | 4 | 2007 | 23 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 3 | 2010 | 408 | 0.100 |
Why?
|
| Ligands | 2 | 2010 | 349 | 0.100 |
Why?
|
| Models, Theoretical | 2 | 2009 | 217 | 0.090 |
Why?
|
| Salvia miltiorrhiza | 1 | 2010 | 5 | 0.090 |
Why?
|
| Flavanones | 1 | 2010 | 8 | 0.090 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2010 | 9 | 0.090 |
Why?
|
| Powders | 1 | 2010 | 17 | 0.090 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2010 | 25 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 935 | 0.090 |
Why?
|
| Trimetrexate | 2 | 2007 | 2 | 0.090 |
Why?
|
| Benzofurans | 1 | 2010 | 21 | 0.090 |
Why?
|
| Bungarotoxins | 1 | 2009 | 21 | 0.090 |
Why?
|
| Bone Marrow | 2 | 2006 | 37 | 0.090 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 2 | 2007 | 53 | 0.090 |
Why?
|
| RNA Polymerase II | 2 | 2007 | 29 | 0.090 |
Why?
|
| Catalytic Domain | 1 | 2010 | 109 | 0.090 |
Why?
|
| Molecular Conformation | 1 | 2010 | 152 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2010 | 85 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase 9 | 2 | 2007 | 37 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2010 | 80 | 0.090 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2009 | 71 | 0.090 |
Why?
|
| Structure-Activity Relationship | 2 | 2007 | 409 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 78 | 0.090 |
Why?
|
| Protein Phosphatase 1 | 2 | 2007 | 62 | 0.090 |
Why?
|
| Sequence Alignment | 1 | 2010 | 265 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2007 | 928 | 0.080 |
Why?
|
| United States | 2 | 2018 | 4223 | 0.080 |
Why?
|
| GABA Antagonists | 1 | 2008 | 29 | 0.080 |
Why?
|
| Protein Folding | 1 | 2009 | 127 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2008 | 34 | 0.080 |
Why?
|
| Amines | 1 | 2008 | 39 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 178 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2010 | 304 | 0.080 |
Why?
|
| Microcomputers | 1 | 2007 | 2 | 0.080 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2007 | 11 | 0.080 |
Why?
|
| Interinstitutional Relations | 1 | 2008 | 38 | 0.080 |
Why?
|
| Diffusion of Innovation | 1 | 2008 | 35 | 0.080 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2007 | 9 | 0.070 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2008 | 107 | 0.070 |
Why?
|
| Folic Acid Antagonists | 1 | 2007 | 3 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2007 | 22 | 0.070 |
Why?
|
| Glutamates | 1 | 2007 | 22 | 0.070 |
Why?
|
| Protein Interaction Mapping | 1 | 2007 | 61 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 45 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2006 | 31 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2007 | 20 | 0.070 |
Why?
|
| Cell Line, Tumor | 6 | 2010 | 2231 | 0.070 |
Why?
|
| Amino Acids | 1 | 2007 | 145 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 219 | 0.070 |
Why?
|
| Pliability | 1 | 2005 | 5 | 0.070 |
Why?
|
| Titrimetry | 1 | 2005 | 8 | 0.070 |
Why?
|
| Bacillus | 1 | 2005 | 8 | 0.070 |
Why?
|
| Protein Denaturation | 1 | 2005 | 43 | 0.070 |
Why?
|
| Enzyme Stability | 1 | 2005 | 35 | 0.070 |
Why?
|
| Drug Administration Schedule | 4 | 2007 | 143 | 0.070 |
Why?
|
| Hydrogen Bonding | 1 | 2005 | 132 | 0.060 |
Why?
|
| Apoptosis | 2 | 2010 | 1398 | 0.060 |
Why?
|
| Thermodynamics | 1 | 2005 | 216 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2007 | 362 | 0.060 |
Why?
|
| Blotting, Western | 4 | 2007 | 859 | 0.060 |
Why?
|
| Cell Growth Processes | 3 | 2007 | 41 | 0.060 |
Why?
|
| Drug Interactions | 3 | 2007 | 141 | 0.050 |
Why?
|
| Mice | 2 | 2010 | 5913 | 0.050 |
Why?
|
| Cell Cycle | 3 | 2007 | 326 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 53 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2005 | 540 | 0.050 |
Why?
|
| Time Factors | 1 | 2005 | 1742 | 0.050 |
Why?
|
| Databases, Protein | 2 | 2010 | 48 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 803 | 0.040 |
Why?
|
| Animals | 3 | 2010 | 15081 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 739 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 974 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1130 | 0.030 |
Why?
|
| Cell Division | 2 | 2010 | 307 | 0.030 |
Why?
|
| Hela Cells | 2 | 2006 | 366 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2006 | 399 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 2379 | 0.030 |
Why?
|
| Mutation | 2 | 2006 | 1095 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 1039 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2010 | 63 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 133 | 0.020 |
Why?
|
| Software Design | 1 | 2009 | 16 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 177 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2010 | 183 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 4268 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 337 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 195 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 259 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2009 | 172 | 0.020 |
Why?
|
| Pentylenetetrazole | 1 | 2008 | 6 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2009 | 70 | 0.020 |
Why?
|
| Receptors, GABA | 1 | 2008 | 25 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 110 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 455 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 5363 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 651 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 6741 | 0.020 |
Why?
|
| Health Services Research | 1 | 2008 | 148 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 132 | 0.020 |
Why?
|
| Proviruses | 1 | 2006 | 29 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2007 | 156 | 0.020 |
Why?
|
| Male | 2 | 2019 | 20025 | 0.020 |
Why?
|
| Serine | 1 | 2006 | 75 | 0.020 |
Why?
|
| Virus Integration | 1 | 2006 | 58 | 0.020 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2006 | 110 | 0.020 |
Why?
|
| Phosphorylase a | 1 | 2005 | 2 | 0.020 |
Why?
|
| Biotinylation | 1 | 2005 | 11 | 0.020 |
Why?
|
| Genes, tat | 1 | 2005 | 8 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2005 | 35 | 0.020 |
Why?
|
| Valine | 1 | 2005 | 31 | 0.020 |
Why?
|
| Phenylalanine | 1 | 2005 | 25 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2005 | 43 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 91 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 83 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2005 | 88 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 131 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 10129 | 0.020 |
Why?
|
| Plasmids | 1 | 2005 | 246 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 252 | 0.020 |
Why?
|
| Transfection | 1 | 2005 | 523 | 0.010 |
Why?
|
| Disease Progression | 1 | 2006 | 601 | 0.010 |
Why?
|
| Adult | 1 | 2019 | 11712 | 0.010 |
Why?
|
| Kinetics | 1 | 2005 | 708 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 366 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 893 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 864 | 0.010 |
Why?
|
| Drug Antagonism | 1 | 2002 | 5 | 0.010 |
Why?
|
| Cell Line | 1 | 2005 | 1354 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 1198 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 502 | 0.010 |
Why?
|
| Female | 2 | 2007 | 20969 | 0.010 |
Why?
|
| HIV Infections | 1 | 2006 | 2303 | 0.010 |
Why?
|